首页> 外文会议>Proceedings of the 29th Annual Meeting of the Controlled Release Society >Insulin complex for subcutaneous protein drug delivery
【24h】

Insulin complex for subcutaneous protein drug delivery

机译:用于皮下蛋白质药物递送的胰岛素复合物

获取原文

摘要

Current dosage regimens of insulin that maintain low serum glucose levels low, in order to minimize the long-term complications of diabetes mellitus, comprise of up to three subcutaneous injections per day. Many strategies have been attempted to develop a biologically active oral, transdermal and transmucosal formulation. However, it is generally acknowledged that protection of the protein drug against degradation by the harsh conditions of the gastrointestinal, subcutaneous barriers and adhesive properties. Thus, compliance with such demanding dosing regimens is very difficult, making the development of descried above formulation forms clearly appealing. In this study, we investigated a novel insulin dosage form linked with polyphenol, extracted from green tea, for insulin delivery in vivo and in vitro.
机译:为了使糖尿病的长期并发症最小化,目前维持低血清葡萄糖水平的胰岛素剂量方案低至每天3次皮下注射。已经尝试了许多策略来开发具有生物活性的口服,透皮和透粘膜制剂。然而,通常公认的是,在胃肠道,皮下屏障和粘附特性的苛刻条件下,保护蛋白质药物免于降解。因此,很难满足这种苛刻的给药方案,使得上述制剂形式的开发显然具有吸引力。在这项研究中,我们研究了一种与绿茶中提取的多酚连接的新型胰岛素剂型,可用于体内和体外的胰岛素输送。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号